Sotagliflozin

Sotagliflozin (INN; trade name Zynquista) is a drug approved in EU for certain patients with type I diabetes.[1]

Sotagliflozin

Clinical data
Trade names	Zynquista
AHFS/Drugs.com	zynquista
Routes of administration	By mouth
ATC code	A10BK06 (WHO)
Legal status
Legal status	US: not approved
Identifiers
CAS Number	1018899-04-1
PubChem CID	24831714
DrugBank	12713
ChemSpider	27289071
UNII	6B4ZBS263Y
KEGG	D10669
CompTox Dashboard (EPA)	DTXSID20144314
ECHA InfoCard	100.231.837
Chemical and physical data
Formula	C21H25ClO5S
Molar mass	424.94 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
InChI InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1 Key:QKDRXGFQVGOQKS-CRSSMBPESA-N

The Food and Drug Administration refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Sanofi.[2][3]

Sotagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins.

References

1. Zynquista approved in EU for certain patients with type I diabetes
2. "Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes - FDA" (PDF).
3. Sanofi (17 January 2019). "Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes". GlobeNewswire News Room.